2915-16-4Relevant articles and documents
Utilizing triazine/pyrimidine acceptor and carbazole-triphenylamine donor based bipolar novel host materials for highly luminescent green phosphorescent OLEDs with lower efficiency roll-off
Braveenth, Ramanaskanda,Ahn, Dae Hyun,Han, Ji-Hun,Moon, Ji Su,Kim, Si Woo,Lee, Hyuna,Qiong, Wu,Kwon, Jang Hyuk,Chai, Kyu Yun
, p. 377 - 384 (2018)
In this work, two novel bipolar host materials were designed, synthesized and applied in green phosphorescent based OLEDs. Both the host materials, 4-(2-(4,6-diphenyl-1,3,5-triazin-2-yl)-9H-carbazol-9-yl)-N,N-diphenylaniline (TRZ 1) and 4-(2-(4,6-diphenylpyrimidin-2-yl)-9H-carbazol-9-yl)-N,N-diphenylaniline (PYR 1) exhibited high thermal stability, with decomposition temperatures of 425 °C and 400 °C, respectively. The triplet energy of PYR 1 (2.63 eV) was higher than that of TRZ 1 (2.44 eV), and facilitated suitable energy transfer to the green dopant. The PYR 1 based green device demonstrated an excellent maximum current efficiency of 48.7 cd/A and external quantum efficiency of 16.4%. Interestingly, the green device with PYR 1 showed an outstanding brightness of 95,870 cd/m2, which is three times greater than that of the reference CBP based device (31,370 cd/m2). The bipolar host PYR 1 is a promising material for high luminescent and low efficiency roll off applications, especially for green PhOLEDs.
Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy
Vuorinen, Aini,Wilkinson, Isabel V.L.,Chatzopoulou, Maria,Edwards, Ben,Squire, Sarah E.,Fairclough, Rebecca J.,Bazan, Noelia Araujo,Milner, Josh A.,Conole, Daniel,Donald, James R.,Shah, Nandini,Willis, Nicky J.,Martínez, R. Fernando,Wilson, Francis X.,Wynne, Graham M.,Davies, Stephen G.,Davies, Kay E.,Russell, Angela J.
supporting information, (2021/05/03)
Duchenne muscular dystrophy is a fatal disease with no cure, caused by lack of the cytoskeletal protein dystrophin. Upregulation of utrophin, a dystrophin paralogue, offers a potential therapy independent of mutation type. The failure of first-in-class utrophin modulator ezutromid/SMT C1100 in Phase II clinical trials necessitates development of compounds with better efficacy, physicochemical and ADME properties and/or complementary mechanisms. We have discovered and performed a preliminary optimisation of a novel class of utrophin modulators using an improved phenotypic screen, where reporter expression is derived from the full genomic context of the utrophin promoter. We further demonstrate through target deconvolution studies, including expression analysis and chemical proteomics, that this compound series operates via a novel mechanism of action, distinct from that of ezutromid.
Hole transporting material and Organic electroluminescent display device using the same
-
Paragraph 0071; 0081-0083, (2021/10/19)
The hole transport material of claim 1, wherein the hole transport material is a hole transport material. Provided are an organic electroluminescent device and an electronic device including the same. Chemical Formula 1. Wherein R is as defined in the specification. The hole transport material has excellent external quantum efficiency, excellent luminous efficiency, brightness, thermal stability, and device lifetime, and can be easily used to produce OLED devices which are stable over a long term.